Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
Poster Presentation Details:
Abstract Title: Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Session: SLE – Treatment Poster II
Date/Time:
Presenter:
Abstract Title: Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Session: Patient Outcomes, Preferences, and Attitudes Poster II
Date/Time:
Presenter:
Abstract Title: Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Session: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More
Date/Time:
Presenter:
The accepted ACR abstracts are currently available on the congress platform here. Following the conference, the presentation materials will be available in the “Scientific Publications” section of Kezar Life Science’s website at www.kezarlifesciences.com.
About Zetomipzomib (KZR-616)
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005862/en/
Investor Contact:
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com
Media Contact:
jdeutsch@soleburystrat.com
Source: